Protective Roles of Xenotropic and Polytropic Retrovirus Receptor 1 (XPR1) in Uremic Vascular Calcification.
Mouse model
Phosphate transporter
Vascular calcification
Vascular smooth muscle cell
XPR1
Journal
Calcified tissue international
ISSN: 1432-0827
Titre abrégé: Calcif Tissue Int
Pays: United States
ID NLM: 7905481
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
11
08
2021
accepted:
08
01
2022
pubmed:
4
2
2022
medline:
18
5
2022
entrez:
3
2
2022
Statut:
ppublish
Résumé
Cellular phosphate transporters play critical roles in the pathogenesis of vascular calcification (VC) in chronic kidney disease (CKD). However, the mechanistic link between VC and xenotropic and polytropic receptor 1 (XPR1), a newly identified phosphate exporter, remains unknown. We developed a new mouse model with rapidly progressive uremic VC in C57BL/6 mice and examined the roles of XPR1. The combination of surgical heminephrectomy and 8 weeks of feeding a customized warfarin and adenine-based diet induced extensive aortic VC in almost all mice. The XPR1 mRNA level in the aorta of CKD mice was significantly lower than those in control mice as early as week 2, when there was no apparent VC, which progressively declined thereafter. Dietary phosphate restriction increased XPR1 mRNA expression in the aorta but reduced aortic VC in CKD mice. In cultured vascular smooth muscle cells (VSMCs), a calcifying medium supplemented with high phosphate and calcium did not affect XPR1 mRNA expression. The XPR1 mRNA expression in cultured VCMCs was also unaffected by administration of indoxyl sulfate or calcitriol deficiency but was decreased by 1-34 parathyroid hormone or fibroblast growth factor 23 supplementation. Furthermore, XPR1 deletion in the cultured VSMCs exacerbated calcification of the extracellular matrix as well as the osteogenic phenotypic switch under the condition of calcifying medium. Our data suggest that XPR1 plays protective roles in the pathogenesis of VC and its decrease in the aorta may contribute to the progression of VC in CKD.
Identifiants
pubmed: 35112184
doi: 10.1007/s00223-022-00947-3
pii: 10.1007/s00223-022-00947-3
doi:
Substances chimiques
Phosphates
0
RNA, Messenger
0
Xenotropic and Polytropic Retrovirus Receptor
0
Xpr1 protein, mouse
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
685-697Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18(9):1731–1740. https://doi.org/10.1093/ndt/gfg414
doi: 10.1093/ndt/gfg414
pubmed: 12937218
Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38(4):938–942. https://doi.org/10.1161/hy1001.096358
doi: 10.1161/hy1001.096358
pubmed: 11641313
Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Gonçalves M, Negrao AP (2004) A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 19(6):1480–1488. https://doi.org/10.1093/ndt/gfh217
doi: 10.1093/ndt/gfh217
pubmed: 15034154
Giachelli CM (2003) Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 14(9 Suppl 4):S300–S304. https://doi.org/10.1097/01.asn.0000081663.52165.66
doi: 10.1097/01.asn.0000081663.52165.66
pubmed: 12939385
Lau WL, Linnes M, Chu EY, Foster BL, Bartley BA, Somerman MJ, Giachelli CM (2013) High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease. Nephrol Dial Transplant 28(1):62–69. https://doi.org/10.1093/ndt/gfs333
doi: 10.1093/ndt/gfs333
pubmed: 23045434
Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E (2003) Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64(5):1653–1661. https://doi.org/10.1046/j.1523-1755.2003.00284.x
doi: 10.1046/j.1523-1755.2003.00284.x
pubmed: 14531797
Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR (2009) Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 20(2):381–387. https://doi.org/10.1681/ASN.2008040349
doi: 10.1681/ASN.2008040349
pubmed: 19073826
pmcid: 2637048
Opdebeeck B, Maudsley S, Azmi A, Maré AD, Leger WD, Meijers B, Verhulst A et al (2019) Indoxyl sulfate and p-cresyl sulfate promote vascular calcification and associate with glucose intolerance. J Am Soc Nephrol 30(5):751–766. https://doi.org/10.1681/ASN.2018060609
doi: 10.1681/ASN.2018060609
pubmed: 30940651
pmcid: 6493976
He X, Jiang H, Gao F, Liang S, Wei M, Chen L (2019) Indoxyl sulfate-induced calcification of vascular smooth muscle cells via the PI3K/Akt/NF-κB signaling pathway. Microsc Res Tech 82(12):2000–2006. https://doi.org/10.1002/jemt.23369
doi: 10.1002/jemt.23369
pubmed: 31448474
Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, Moe OW (2011) Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 22(1):124–136. https://doi.org/10.1681/ASN.2009121311
doi: 10.1681/ASN.2009121311
pubmed: 21115613
pmcid: 3014041
O’Neill WC, Lomashvili KA, Malluche HH, Faugere MC, Riser BL (2011) Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 79(5):512–517. https://doi.org/10.1038/ki.2010.461
doi: 10.1038/ki.2010.461
pubmed: 21124302
Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM et al (2006) Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 26(9):2117–2124. https://doi.org/10.1161/01.ATV.0000236428.91125.e6
doi: 10.1161/01.ATV.0000236428.91125.e6
pubmed: 16840715
Yamada S, Tokumoto M, Tsuruya K, Tatsumoto N, Noguchi H, Kitazono T, Ooboshi H (2015) Fetuin-A decrease induced by a low-protein diet enhances vascular calcification in uremic rats with hyperphosphatemia. Am J Physiol Renal Physiol 309(8):744–754. https://doi.org/10.1152/ajprenal.00017.2015
doi: 10.1152/ajprenal.00017.2015
Yamada S, Tokumoto M, Tatsumoto N, Taniguchi M, Noguchi H, Nakano T, Masutani K et al (2014) Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. Am J Physiol Renal Physiol 306(12):1418–1428. https://doi.org/10.1152/ajprenal.00633.2013
doi: 10.1152/ajprenal.00633.2013
Yamada S, Taniguchi M, Tokumoto M, Toyonaga J, Fujisaki K, Suehiro T, Noguchi H et al (2012) The antioxidant tempol ameliorates arterial medial calcification in uremic rats: important role of oxidative stress in the pathogenesis of vascular calcification in chronic kidney disease. J Bone Miner Res 27(2):474–485. https://doi.org/10.1002/jbmr.539
doi: 10.1002/jbmr.539
pubmed: 21987400
Zhao MM, Xu MJ, Cai Y, Zhao G, Guan Y, Kong W, Tang C et al (2011) Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. Kidney Int 79(10):1071–1079. https://doi.org/10.1038/ki.2011.18
doi: 10.1038/ki.2011.18
pubmed: 21368742
Carracedo M, Artiach G, Arnardottir H, Back M (2019) The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification. Semin Immunopathol 41(6):757–766. https://doi.org/10.1007/s00281-019-00767-y
doi: 10.1007/s00281-019-00767-y
pubmed: 31696250
pmcid: 6881483
Sanchez-Duffhues G, Garcia de Vinuesa A, van de Pol V, Geerts ME, de Vries MR, Janson SG, van Dam H et al (2019) Inflammation induces endothelial-to-mesenchymal transition and promotes vascular calcification through downregulation of BMPR2. J Pathol 247(3):333–346. https://doi.org/10.1002/path.5193
doi: 10.1002/path.5193
pubmed: 30430573
pmcid: 6590480
Chavkin NW, Chia JJ, Crouthamel MH, Giachelli CM (2015) Phosphate uptake-independent signaling functions of the type III sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells. Exp Cell Res 333(1):39–48. https://doi.org/10.1016/j.yexcr.2015.02.002
doi: 10.1016/j.yexcr.2015.02.002
pubmed: 25684711
pmcid: 4387109
Yamada S, Leaf EM, Chia JJ, Cox TC, Speer MY, Giachelli CM (2018) PiT-2, a type III sodium-dependent phosphate transporter, protects against vascular calcification in mice with chronic kidney disease fed a high-phosphate diet. Kidney Int 94(4):716–727. https://doi.org/10.1016/j.kint.2018.05.015
doi: 10.1016/j.kint.2018.05.015
pubmed: 30041812
pmcid: 6211801
Giovannini D, Touhami J, Charnet P, Sitbon M, Battini JL (2013) Inorganic phosphate export by the retrovirus receptor XPR1 in metazoans. Cell Rep 3(6):1866–1873. https://doi.org/10.1016/j.celrep.2013.05.035
doi: 10.1016/j.celrep.2013.05.035
pubmed: 23791524
Yao XP, Zhao M, Wang C, Guo XX, Su H, Dong EL, Chen HT et al (2017) Analysis of gene expression and functional characterization of XPR1: a pathogenic gene for primary familial brain calcification. Cell Tissue Res 370(2):267–273. https://doi.org/10.1007/s00441-017-2663-3
doi: 10.1007/s00441-017-2663-3
pubmed: 28766044
Legati A, Giovannini D, Nicolas G, Lopez-Sanchez U, Quintans B, Oliveira JR, Sears RL et al (2015) Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. Nat Genet 47(6):579–581. https://doi.org/10.1038/ng.3289
doi: 10.1038/ng.3289
pubmed: 25938945
pmcid: 4516721
Lopez-Sanchez U, Tury S, Nicolas G, Wilson MS, Jurici S, Ayrignac X, Courgnaud V et al (2020) Interplay between primary familial brain calcification-associated SLC20A2 and XPR1 phosphate transporters requires inositol polyphosphates for control of cellular phosphate homeostasis. J Biol Chem 295(28):9366–9378. https://doi.org/10.1074/jbc.RA119.011376
doi: 10.1074/jbc.RA119.011376
pubmed: 32393577
pmcid: 7363132
Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386(6620):78–81. https://doi.org/10.1038/386078a0
doi: 10.1038/386078a0
pubmed: 9052783
O’Young J, Liao Y, Xiao Y, Jalkanen J, Lajoie G, Karttunen M, Goldberg HA et al (2011) Matrix Gla protein inhibits ectopic calcification by a direct interaction with hydroxyapatite crystals. J Am Chem Soc 133(45):18406–18412. https://doi.org/10.1021/ja207628k
doi: 10.1021/ja207628k
pubmed: 21961692
Kawata T, Nagano N, Obi M, Miyata S, Koyama C, Kobayashi N, Wakita S et al (2008) Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 74(10):1270–1277. https://doi.org/10.1038/ki.2008.407
doi: 10.1038/ki.2008.407
pubmed: 18813289
Ter Braake AD, Smit AE, Bos C, van Herwaarden AE, Alkema W, van Essen HW, Bravenboer N et al (2020) Magnesium prevents vascular calcification in Klotho deficiency. Kidney Int 97(3):487–501. https://doi.org/10.1016/j.kint.2019.09.034
doi: 10.1016/j.kint.2019.09.034
pubmed: 31866113
Diaz-Tocados JM, Peralta-Ramirez A, Rodriguez-Ortiz ME, Raya AI, Lopez I, Pineda C, Herencia C et al (2017) Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats. Kidney Int 92(5):1084–1099. https://doi.org/10.1016/j.kint.2017.04.011
doi: 10.1016/j.kint.2017.04.011
pubmed: 28760336
Sakaguchi Y, Hamano T, Obi Y, Monden C, Oka T, Yamaguchi S, Matsui I et al (2019) A randomized trial of magnesium oxide and oral carbon absorbent for coronary artery calcification in predialysis CKD. J Am Soc Nephrol 30(6):1073–1085. https://doi.org/10.1681/ASN.2018111150
doi: 10.1681/ASN.2018111150
pubmed: 31036759
pmcid: 6551769
Li X, Gu C, Hostachy S, Sahu S, Wittwer C, Jessen HJ, Fiedler D et al (2020) Control of XPR1-dependent cellular phosphate efflux by InsP8 is an exemplar for functionally-exclusive inositol pyrophosphate signaling. Proc Natl Acad Sci USA 117(7):3568–3574. https://doi.org/10.1073/pnas.1908830117
doi: 10.1073/pnas.1908830117
pubmed: 32019887
pmcid: 7035621
Xu X, Li X, Sun H, Cao Z, Gao R, Niu T, Wang Y et al (2020) Murine placental-fetal phosphate dyshomeostasis caused by an Xpr1 deficiency accelerates placental calcification and restricts fetal growth in late gestation. J Bone Miner Res 35(1):116–129. https://doi.org/10.1073/pnas.1908830117
doi: 10.1073/pnas.1908830117
pubmed: 31498925
Kuro-o M (2013) A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney Int Supple 3(5):420–426. https://doi.org/10.1038/kisup.2013.88
doi: 10.1038/kisup.2013.88
Ter Braake AD, Eelderink C, Zeper LW, Pasch A, Bakker SJL, de Borst MH, Hoenderop JGJ et al (2020) Calciprotein particle inhibition explains magnesium-mediated protection against vascular calcification. Nephrol Dial Transplant 35(5):765–773. https://doi.org/10.1093/ndt/gfz190
doi: 10.1093/ndt/gfz190
pubmed: 31605492
Sakaguchi Y, Hamano T, Matsui I, Oka T, Yamaguchi S, Kubota K, Shimada K et al (2019) Low magnesium diet aggravates phosphate-induced kidney injury. Nephrol Dial Transplant 34(8):1310–1319. https://doi.org/10.1093/ndt/gfy358
doi: 10.1093/ndt/gfy358
pubmed: 30535376
Omede F, Zhang S, Johnson C, Daniel E, Zhang Y, Fields TA, Boulanger J et al (2020) Dietary phosphate restriction attenuates polycystic kidney disease in mice. Am J Physiol Renal Physiol 318(1):35–42. https://doi.org/10.1152/ajprenal.00282.2019
doi: 10.1152/ajprenal.00282.2019
Damment S, Secker R, Shen V, Lorenzo V, Rodriguez M (2011) Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure. Nephrol Dial Transplant 26(6):1803–1812. https://doi.org/10.1093/ndt/gfq682
doi: 10.1093/ndt/gfq682
pubmed: 21098011
Shuvy M, Abedat S, Eliaz R, Abu-Rmeileh I, Abu-Snieneh A, Ben-Dov IZ, Meir K et al (2019) Hyperphosphatemia is required for initiation but not propagation of kidney failure-induced calcific aortic valve disease. Am J Physiol Heart Circ Physiol 317(4):695–704. https://doi.org/10.1152/ajpheart.00765.2018
doi: 10.1152/ajpheart.00765.2018
Tani T, Orimo H, Shimizu A, Tsuruoka S (2017) Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. Sci Rep 7(1):2233. https://doi.org/10.1038/s41598-017-02351-6
doi: 10.1038/s41598-017-02351-6
pubmed: 28533541
pmcid: 5440375
Yoshida T, Yamashita M, Horimai C, Hayashi M (2017) Smooth muscle-selective nuclear factor-κB inhibition reduces phosphate-induced arterial medial calcification in mice with chronic kidney disease. J Am Heart Assoc 6(11):e007248. https://doi.org/10.1161/JAHA.117.00724
doi: 10.1161/JAHA.117.00724
pubmed: 29146611
pmcid: 5721793
Van TV, Watari E, Taketani Y, Kitamura T, Shiota A, Tanaka T, Tanimura A et al (2012) Dietary phosphate restriction ameliorates endothelial dysfunction in adenine-induced kidney disease rats. J Clin Biochem Nutr 51(1):27–32. https://doi.org/10.3164/jcbn.11-96
doi: 10.3164/jcbn.11-96
pubmed: 22798709
pmcid: 3391860
Dos Santos IF, Sheriff S, Amlal S, Ahmed RPH, Thakar CV, Amlal H (2019) Adenine acts in the kidney as a signaling factor and causes salt- and water-losing nephropathy: early mechanism of adenine-induced renal injury. Am J Physiol Renal Physiol 316(4):743–757. https://doi.org/10.1152/ajprenal.00142.2018
doi: 10.1152/ajprenal.00142.2018
Mace ML, Olgaard K, Lewin E (2020) New aspects of the kidney in the regulation of fibroblast growth factor 23 (FGF23) and mineral homeostasis. Int J Mol Sci 21(22):8810. https://doi.org/10.3390/ijms21228810
doi: 10.3390/ijms21228810
pmcid: 7699902
Edmonston D, Wolf M (2020) FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol 16(1):7–19. https://doi.org/10.1038/s41581-019-0189-5
doi: 10.1038/s41581-019-0189-5
pubmed: 31519999